Navigation Links
Solta Medical Reports First Quarter 2013 Results
Date:5/1/2013

HAYWARD, Calif., May 1, 2013 /PRNewswire/ -- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced results for the first quarter ended March 31, 2013. Revenue for the first quarter was $34.5 million, an increase of $2.1 million, or 6%, as compared to the first quarter of 2012. The year-over-year revenue increase consisted primarily of $1.5 million from sales of VASER systems and $2.1 million from sales of treatment tips and other consumables, partially offset by a decline in sales of Liposonix systems in North America.

International revenue for the quarter rose year-over-year by 34% to $20.7 million with Asia Pacific up 40% and EMEA rising by 20%. North America revenue declined year-over-year by 19% to $13.8 million. Revenue from treatment tips and consumables for the quarter was $18.9 million, a year-over-year increase of $2.1 million or 13%, which included year-over-year growth both in North America and international markets of 10% and 15%, respectively.

"Our first quarter was softer than we had planned due to issues that have been identified and corrected," said Stephen J. Fanning, Chairman, President and CEO of Solta.  "In North America, our acquisition of Sound Surgical during the critical last month of the quarter led to some internal disruption impacting sales.  Additionally, a manufacturing issue with the Liposonix transducer treatment tip adversely affected customer reorders and our ability to demonstrate our Liposonix system to potential new customers in North America.  These developments masked the strong revenue growth generated by our international operations as well as the continued top line benefit of our recurring business model."

"Over the past month, we have been rebuilding the Liposonix momentum in North America.  At the same time, we are capitalizing on the synergies we envision from the Sound Surgical acquisition.  As a result, we fully anticipate improved growth in the second quarter," added Mr. Fanning. 

GAAP net loss for the quarter was $2.6 million, or $0.04 per share, as compared to GAAP net loss of $8.8 million, or $0.14 per share, reported for the first quarter of 2012. Non-GAAP net loss for the quarter was $0.8 million, or $0.01 per share, as compared to a non-GAAP net loss of $0.8 million, or $0.01 per share, for same period last year. Non-GAAP adjusted EBITDA for the quarter was $0.9 million compared to $0.6 million for the same period last year.

The Company's GAAP results for the quarter include $3.7 million of amortization, severance, and other acquisition related charges, $1.2 million of non-cash stock based compensation charges, and a $3.1 million credit for the fair value reassessment of the expected earn out payments associated with the acquisition of Liposonix and Sound Surgical. The Company provides non-GAAP financial measures that exclude these charges and adjustments. A reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

"We expect to achieve a higher amount of cost synergies than originally anticipated from the acquisition of Sound Surgical during the remainder of 2013.  Combined with some operating expense reductions recently implemented, we believe that despite the slower than expected first quarter growth rate, we can achieve our profitability targets for the full year," said Mr. Fanning.

Financial Outlook for 2013Based on the first quarter results, the Company updated its financial outlook for 2013 as follows:

  • The company revised its revenue outlook for full year 2013 to approximately $180 million, which would represent year-over-year revenue growth of approximately $36 million, or 25%, compared to full year 2012 revenue of $144.5 million. The company's previous revenue outlook for 2013 was a range of $182 million to $191 million.
  • The company reiterated its outlook for non-GAAP gross margin. Non-GAAP gross margin is expected to be in the range of 65% to 68% for the full year 2013.  Non-GAAP gross margin excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP gross margin for the first quarter 2013 was 67%.
  • The company reiterated its outlook for non-GAAP operating income. Non-GAAP operating income is expected to be in the range of $13 million to $16 million for the full year 2013. Non-GAAP operating income for the first six months of 2013 is expected to be in the range $3 million to $4 million. Non-GAAP operating income excludes non-cash amortization charges, non-cash stock based compensation charges, severance costs, and acquisition related adjustments. Non-GAAP operating income for the first quarter was $59,000.
  • Non-GAAP PresentationTo supplement the condensed consolidated financial information presented on a GAAP basis, management has provided non-GAAP gross margin, non-GAAP operating income (loss), non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP earnings (loss) per share measures that exclude the impact of acquisition related adjustments, severance costs, acquisition related costs, and stock-based compensation expenses.  The Company believes that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of the Company's ongoing operating results and trends, compared with historical results.  This presentation is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods and against our internally developed targets.  There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures.  Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures attached to this release.

    Conference Call Information The Company will host a conference call and webcast today, Wednesday, May 1, 2013, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss the financial results and current corporate developments. The dial-in number for the conference call is 877-941-0844 for domestic participants and 480-629-9835 for international participants.

    To access the live webcast of the call, go to Solta Medical's website at www.solta.com and click on Investor Relations. An archived webcast will also be available at www.solta.com.

    About Solta Medical, Inc.Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative solutions with proven efficacy and safety backed by over 10 years of clinical study and research. The company offers aesthetic energy devices for skin resurfacing and rejuvenation, acne reduction, body contouring and skin tightening, as well as tools and accessories to optimize the latest liposuction techniques. The Solta Medical portfolio includes the well-known brands Thermage®, Fraxel®, Clear + Brilliant®, Liposonix®, Isolaz®, CLARO®, VASERlipo, VASERshape, VASERsmooth, VentX®, PowerX®, TouchView®, and Origins, which collectively make up a comprehensive platform to address a range of aesthetic skin and body issues. More than two and a half million procedures have been performed with Solta Medical's products around the world. Solta Medical is headquartered in Hayward, CA with field teams and regional offices worldwide.

    Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the ability to improve operating leverage, the close of the Sound Surgical acquisition, and the financial outlook for 2013. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Solta Medical's actual results to differ materially from the statements contained herein. Factors that might cause such a difference include the risk that physician adoption of our systems does not grow, the risk that customers do not continue to purchase treatment tips, the possibility that the market for the sale of new products does not develop as expected, and the risks relating to Solta Medical's ability to achieve its stated financial goals as a result of, among other things, economic conditions and consumer and physician confidence causing changes in consumer and physician spending habits that affect demand for our products and treatments. Further information on potential risk factors that could affect Solta Medical's business and its financial results are detailed in its Form 10-K for the year ended December 31, 2012, and other reports as filed from time to time with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, especially guidance on future financial performance, which speaks only as of the date they are made. Solta Medical undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

     

     Solta Medical, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands of dollars, except share and per share data)(unaudited)Three Months EndedMarch 31,20132012Net revenue 

    $34,523$32,454Cost of revenue 

    12,84412,211Gross margin 

    21,67920,243Operating expenses:Sales and marketing 

    14,20713,946Research and development 

    5,3355,305General and administrative 

    6,9774,660Remeasurement of contingent consideration liability

    (3,100)4,700Total operating expenses 

    23,41928,611Loss from operations 

    (1,740)(8,368)Interest income

    93Interest expense

    (692)(351)Other expense, net

    (95)(26)Loss before income taxes 

    (2,518)(8,742)Income tax provision

    7757Net loss

    ($2,595)($8,799)Net loss per share:Basic

    ($0.04)($0.14)Diluted

    ($0.04)($0.14)Weighted average shares outstanding used in calculating net lossper share:Basic

    72,113,00761,352,524Diluted

    72,113,00761,352,524 

     Solta Medical, Inc.NON-GAAP RECONCILIATION OF GROSS MARGIN, OPERATING INCOME (LOSS), EBITDA, NET INCOME (LOSS) AND NET INCOME (LOSS) PER SHARE  (in thousands, except share and per share data)(unaudited)Three Months EndedMarch 31,20132012GAAP Gross margin

    $21,679$20,243GAAP gross margin as % of sales

    63%62%Non-GAAP adjustments to gross margin:GAAP Gross margin

    $21,679$20,243Amortization and other non-cash acquisition related charges

    1,4381,658Stock-based compensation

    136112Non-GAAP gross margin

    $23,253$22,013Non-GAAP gross margin as % of sales

    67%68%GAAP loss from operations

    ($1,740)($8,368)Non-GAAP adjustments to net loss from operations:Amortization and other non-cash acquisition related charges

    1,9962,017Remeasurement of contingent consideration liability

    (3,100)4,700Acquisition-related expenses

    1,39493Severance expenses

    31330Stock-based compensation

    1,2001,140Non-GAAP income (loss) from operations

    $63($388)Depreciation expenses

    875938Non-GAAP Adjusted EBITDA

    $938$550GAAP net loss($2,595)($8,799)Non-GAAP adjustments to net loss:Amortization and other non-cash acquisition related charges

    1,9962,017Remeasurement of contingent consideration liability

    (3,100)4,700Acquisition-related expenses

    1,39493Severance expenses

    31330Stock-based compensation

    1,2001,140Non-GAAP net loss

    ($792)($819)GAAP basic net loss per share

    ($0.04)($0.14)Non-GAAP adjustments to basic loss per share:Amortization and other non-cash acquisition related charges

    $0.03$0.03Remeasurement of contingent consideration liability

    ($0.04)$0.08Acquisition-related expenses

    $0.02$0.00Severance expenses

    $0.00$0.00Stock-based compensation

    $0.02$0.02Non-GAAP basic net loss per share

    ($0.01)($0.01)Non-GAAP diluted net loss per share

    ($0.01)($0.01)GAAP weighted average shares outstanding used in calculating basic net loss per share

    72,113,00761,352,524GAAP weighted average shares outstanding used in calculating diluted net loss per share

    72,113,00761,352,524Adjustments for dilutive potential common stock

    --Weighted average shares outstanding used in calculating non-GAAP diluted net loss per share

    72,113,00761,352,524 

     

     Solta Medical, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands of dollars, except share and per share data)(unaudited)March 31,December 31,20132012ASSETSCurrent assets:Cash and cash equivalents 

    $26,990$38,097Accounts receivable, net

    21,60720,570Inventories

    21,25416,611Prepaid expenses and other current assets 

    5,9528,476Total current assets 

    75,80383,754Property and equipment, net 

    7,6946,401Purchased intangible assets, net

    61,23242,428Goodwill

    103,99896,620Other assets 

    818520Total assets 

    $249,545$229,723LIABILITIES AND STOCKHOLDERS' EQUITYLiabilities:Accounts payable 

    $9,393$7,283Accrued liabilities 

    13,98017,343Current portion of contingent consideration liability

    34,20021,400Current portion of deferred revenue 

    3,7123,985Short-term borrowings

    9,6698,345Customer deposits 

    662637Total current liabilities 

    71,61658,993Deferred revenue, net of current portion 

    656683Term loan, net of current portion

    15,37618,063Non-current tax liabilities

    2,4922,478Contingent consideration liability

    29,00038,500Other  liabilities 

    1,196899Total liabilities 

    120,336119,616Stockholders' equity:Common stock, $0.001 par value:100,000,000 shares authorized79,337,751 and 68,795,987 shares issued and outstanding at March 31, 2013 and December 31, 2012

    7969Additional paid-in capital 

    242,176220,489Accumulated deficit 

    (113,046)(110,451)Total stockholders' equity

    129,209110,107Total liabilities and stockholders' equity

    $249,545$229,723 


    '/>"/>
    SOURCE Solta Medical, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Solta Medical to Present at the 25th Annual ROTH Growth Stock Conference on March 18, 2013
    2. Solta Medical Reports Fourth Quarter and Full Year 2012 Results
    3. Solta Medical to Report Fourth Quarter 2012 Results Release and Host Conference Call on February 19, 2013
    4. Solta Medical to Present at the Leerink Swann Global Healthcare Conference in New York on February 14, 2013
    5. Solta Medical to Acquire Sound Surgical Technologies
    6. Solta Medical Reports Third Quarter Results
    7. Solta Medical And BTL Industries Resolve Patent Dispute
    8. Solta Medical to Present at the 32nd Annual Canaccord Growth Conference
    9. Solta Medical, Inc. Closes Public Offering of Common Stock
    10. Solta Medical, Inc. Prices $15 Million Public Offering of Common Stock
    11. Solta Medical, Inc. Announces Proposed Public Offering of Common Stock
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... , Feb. 5, 2016 ... of the "Global Obstetrics Partnering 2010-2016: ... profile to their offering. --> ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> Research ...
    (Date:2/4/2016)... Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... structural heart disease and critical care monitoring, announced today ... (ASR) agreement with Morgan Stanley & Co. LLC to ... is part of the Company,s previously authorized program to ... stock.  --> --> ...
    (Date:2/4/2016)... -- Worldwide Radiology Oncology surgical robot markets are ... systems provide a way to improve traditional open ... systems pinpoint the delivery of radiation precisely, eliminating ... problem previously, limiting the quantity of radiation that ... far beyond what has been available, promising a ...
    Breaking Medicine Technology:
    (Date:2/8/2016)... , ... February 08, 2016 , ... If you are ... to handle, you are not alone. According to the Center for Disease Control and ... stroke, type 2 diabetes and certain types of cancer, some of the leading causes ...
    (Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates Insurance ... new community enrichment program, has teamed up with Citizens Opposed to Domestic Abuse in ... intimate abuse. To support all those victimized by the fear of violence in their ...
    (Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
    (Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
    (Date:2/8/2016)... ... 2016 , ... Eating disorders and post-traumatic stress disorder (PTSD) ... men with eating disorders report a history of trauma, research suggests that it ... eating disorder. , At the 2016 iaedp Symposium, the workshop, “What Eating ...
    Breaking Medicine News(10 mins):